Intelligence Report · ~15 min read
Contraception · Hormonal Therapeutic Area Assessment
2 signals · 1 insights · 10 regulatory precedents
Type
Therapeutic Area AssessmentGenerated
Jul 23, 2026
Confidence
Moderate Confidence · 67%
Evidence
13 items
Sources
2
Executive Summary
Synthesized assessment from linked signals, findings, and evidence relationships.
Therapeutic area assessment for Contraception · Hormonal integrates 2 signals, 1 executive insights, and 10 regulatory precedents from the Humanexa intelligence graph. 0 portfolio assets maintain indication overlap in this area. Regulatory and competitive dynamics require cross-functional monitoring across linked entities.
Key Developments
Material intelligence events ranked by strategic relevance.
- signalJul 21, 2026
FDA Accepts Supplement for Implanon by Organon
The FDA has accepted a supplemental application for Implanon, a contraceptive implant containing etonogestrel.
View detail - signalJul 8, 2026
FDA Grants AP Status for Introvale (ANDA079064) by Xiromed
The FDA has granted Abbreviated Approval (AP) status for Introvale, a contraceptive containing Ethinyl Estradiol and Levonorgestrel.
View detail - regulatoryJul 21, 2026
Data Standards Program Strategic Plan and Board
The Data Standards Strategy reinforces CDER’s ongoing commitment to the development, implementation, and maintenance of a comprehensive data standards program that will facilitate the efficient and effective review of regulatory submissions. This helps bring safe and effective products to market.
View detail - regulatoryJul 21, 2026
Notice: Register of authorised online sellers of medicines in Northern Ireland
This register contains all websites that are authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) to sell medicines online, in Northern Ireland.
View detail - regulatoryJul 21, 2026
Understanding the Risks of Compounded Drugs
Compounded drugs are not FDA-approved. This means the agency does not verify their safety, effectiveness or quality before they are marketed. Learn more.
View detail - regulatoryJul 21, 2026
FDA AP — ELOCON (SUPPL)
Application NDA019543. Sponsor: ORGANON. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: MOMETASONE FUROATE.
View detail - insightJul 8, 2026
Xiromed's Introvale Approval Enhances Competitive Position in Contraception Market
The FDA's grant of Abbreviated Approval status for Introvale positions Xiromed favorably within the contraceptive market, potentially disrupting competitors. Portfolio teams must evaluate the implications for market share and competitive strategies in response to this development. Regulatory context from FDA (FDA AP — INTROVALE (SUPPL)) supports the near-term read. Assessment grounded in 18 ranked evidence items (9 high-relevance).
View detail
Strategic Implications
Portfolio and competitive decisions informed by this intelligence profile.
Executive insights surface 1 risk-calibrated assessments for portfolio review. 10 Regunera precedents provide regulatory context for pathway and timing decisions. Monitor 0 companies with active signal exposure for competitive and portfolio shifts.
Supporting Evidence
Evidence-backed items with source attribution and confidence disclosure.
Data Standards Program Strategic Plan and Board
77%The Data Standards Strategy reinforces CDER’s ongoing commitment to the development, implementation, and maintenance of a comprehensive data standards program that will facilitate the efficient and effective review of regulatory submissions. This helps bring safe and effective products to market.
Source: FDA
View evidenceNotice: Register of authorised online sellers of medicines in Northern Ireland
83%This register contains all websites that are authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) to sell medicines online, in Northern Ireland.
Source: MHRA
View evidenceUnderstanding the Risks of Compounded Drugs
95%Compounded drugs are not FDA-approved. This means the agency does not verify their safety, effectiveness or quality before they are marketed. Learn more.
Source: FDA
View evidenceFDA AP — ELOCON (SUPPL)
66%Application NDA019543. Sponsor: ORGANON. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: MOMETASONE FUROATE.
Source: FDA
View evidenceVerified Clinical Benefit | Cancer Accelerated Approvals
84%This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications with postmarketing trials that have verified clinical benefit and for which traditional approval has been subsequently granted for the specific indication.
Source: FDA
View evidenceFDA AP — PREDNISONE (ORIG)
77%Application ANDA218035. Sponsor: DR REDDYS. Submission status: AP. Submission type: ORIG. Review priority: STANDARD. Active ingredients: PREDNISONE.
Source: FDA
View evidenceXiromed's Introvale Approval Enhances Competitive Position in Contraception Market
67%The FDA's grant of Abbreviated Approval status for Introvale positions Xiromed favorably within the contraceptive market, potentially disrupting competitors. Portfolio teams must evaluate the implications for market share and competitive strategies in response to this development. Regulatory context from FDA (FDA AP — INTROVALE (SUPPL)) supports the near-term read. Assessment grounded in 18 ranked evidence items (9 high-relevance).
Source: Humanexa Insight
View evidence
Related Intelligence
Deep links to signals, insights, companies, and assets in the Humanexa graph.
Signals
- FDA Accepts Supplement for Implanon by Organon
Regulatory Approval
- FDA Grants AP Status for Introvale (ANDA079064) by Xiromed
Regulatory Approval
Insights
- Xiromed's Introvale Approval Enhances Competitive Position in Contraception Market
Contraception · Hormonal